Additionally, the lymphocyte predominant subgroups of triple negative tumors and hormone-receptor negative and HER2-positive (HR-/HER2+) tumors show a favorable response to systemic therapy, but, interestingly, this is not the case in hormone-receptor positive breast cancers. Here, ERBB2 is linked to breast carcinoma.